Developmental and epileptic encephalopathies (DEEs) make up a diverse range of conditions that generally present with significant epileptic seizures and electroencephalogram (EEG) abnormalities. DEEs can significantly impact children and adults living with the condition, as well as caregivers. Patients within …
Biomarker and molecular testing to help oncologists match patients with the best cancer treatment can be challenging in the community oncology setting and in underserved communities. At present, patients with cancer in racially or ethnicly underserved communities are not receiving …
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune, neuro-muscular condition impacting the myelin that insulates and protects peripheral nerves causing mobility and sensory impairment. Standard therapies for CIPD have been recommended for decades, however, there are many unmet needs related …
Health inequities in the diagnosis, treatment, and outcomes of gastrointestinal disorders significantly impact racial, ethnic, and immigrant populations. Patients born outside the U.S. are less likely to be diagnosed with inflammatory bowel disease (IBD) before age 16 and often face …
Crohn’s disease (CD) can cause progressive bowel damage, impaired quality of life, and permanent disability. Severity and presentation can vary widely from person to person, necessitating an individualized treatment approach. The use of more readily available imaging modalities such as …
Ulcerative colitis (UC) affects around three million people in the United States. Delays in treatment coverage approval, costs of managing the disease, and uncertainties around new treatment options significantly impact how well patients react to treatment, and short- and long-term …
Cytomegalovirus (CMV) remains a major concern in both solid organ transplantation (SOT) and hematopoietic stem cell transplant (HSCT), primarily due to challenges related to treatment selection and monitoring, management of drug-related adverse events, and resistant/refractory disease. To minimize the impact …
New and emerging therapies for hemophilia are transforming clinical pathways in patient care. Such therapies include extended half-life products, non-factor/rebalancing therapies, and even gene therapies. But while this expanding armamentarium is a triumph in the evolution of hemophilia prophylaxis and …
